DNLI
DNLI
US24823R1059
Denali Therapeutics Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
555.342.000 501.878.000
10.7%
Operating Income -555.342.000 -501.878.000
10.7%
Pretax Income -512.438.000 -422.705.000
21.2%
Net Income Common Stockholders -512.540.000 -422.773.000
21.2%
-- --
--
-- --
--
ende